Compare Gilead Sciences, Inc. (GILD) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wipro Limited — how do they compare? Gilead Sciences, Inc. trades at $133.21 (market cap $163.51B), while Wipro Limited trades at $1.82 (market cap $18.31B). The key difference: Gilead Sciences, Inc. is far larger — about 8.9× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (10.42%). Which is the better fit depends on your goals.
| GILD | WIT | |
|---|---|---|
Market Cap | $163.51B | $18.31B |
Sector | Health | Technology |
52-Week High | $155.80 | $3.06 |
52-Week Low | $108.22 | $1.82 |
Enterprise Value | $178.05B | $14.69B |
Dividend Yield | 2.49% | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
WIT trades at $1.84, down 3.16% today, with bearish technical signals and mixed analyst sentiment. The company reported three consecutive quarterly EPS misses but maintains solid profitability with 14.25% net margin and 15.4% ROE. Recent news highlights AI partnerships and revenue challenges, with the stock showing weak momentum amid cautious client spending in the IT services sector.
The outlook remains cautious with near-term revenue pressure offset by AI transformation initiatives. Investment opportunity lies in valuation multiples below sector averages, while risks include persistent earnings misses and competitive IT services market dynamics. Wall Street shows divided sentiment with 19% buy ratings versus 33% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
